Citing "severe liquidity problems," breast cancer detection firm HumaScan of Cranford, NJ, has laid off most of its work force and is pursuing strategic alternatives that could result in the sale of the company. The firm said it is taking the approach
Citing "severe liquidity problems," breast cancer detection firm HumaScan of Cranford, NJ, has laid off most of its work force and is pursuing strategic alternatives that could result in the sale of the company. The firm said it is taking the approach due to slow sales of its BreastAlert TDS system, which is designed to detect breast pathology by measuring differences in skin temperature in breast tissue.
Sales of BreastAlert TDS began earlier this year, but the product has generated revenues of only $57,000 in the company's most recent quarter (end-June). That has led to a cash-flow shortage at the firm, a situation that has been complicated by the company's declining stock price and generally turbulent conditions on Wall Street.
HumaScan executives said on Nov. 4 that the company has reduced its personnel from 17 employees to four. The company is also seeking additional funding, with the option of selling the firm if necessary.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).